Zhang Qing-yun, Wang Ji-wei, Yu Jin-ming
Institute of Clinical Epidemiology, Key Lab of Health Technology Assessment (Ministry of Health), School of Public Health, Fudan University, Shanghai 200032, China.
Institute of Clinical Epidemiology, Key Lab of Health Technology Assessment (Ministry of Health) , School of Public Health, Fudan University, Shanghai 200032, China. Email:
Zhonghua Yi Xue Za Zhi. 2013 Nov 19;93(43):3445-9.
To evaluate the efficacy and safety of Kuntai Capsule and Estrogen for Menopausal Syndrome.
Related randomized controlled trials about Kuntai capsule and estrogen in recent 10 years were collected by various kinds of database according to strict inclusion and exclusion criteria. Valid data were extracted to conduct meta-analysis by RevMan5.0.
A total of 196 articles were retrieved, but only 6 were finally included. Meta-analysis showed that no significant differences were observed in Kupperman score between Kuntai group and estrogen [WMD = 0.22, 95%CI (-1.14, 1.58), P > 0.05]. While E(2) level was significantly higher in estrogen group than that in Kuntai [WMD = -59.59, 95%CI(-87.35, -31.83), P < 0.01]. The incidence of adverse effects was significantly lower in Kuntai group compared to the estrogen group [RR = 0.61, 95%CI(0.45,0.83), P < 0.01].
Kuntai can improve symptoms of menopausal syndrome effectively as the same as estrogen and tends to have lower incidence of adverse effects.
评价坤泰胶囊与雌激素治疗绝经综合征的疗效及安全性。
通过各种数据库，根据严格的纳入和排除标准收集近10年有关坤泰胶囊和雌激素的相关随机对照试验。提取有效数据，采用RevMan5.0进行荟萃分析。
共检索到196篇文章，但最终仅纳入6篇。荟萃分析显示，坤泰组与雌激素组在Kupperman评分上无显著差异[加权均数差（WMD）=0.22，95%置信区间（CI）（-1.14，1.58），P>0.05]。而雌激素组的雌二醇（E₂）水平显著高于坤泰组[WMD=-59.59，95%CI（-87.35，-31.83），P<0.01]。与雌激素组相比，坤泰组不良反应发生率显著更低[风险比（RR）=0.61，95%CI（0.45，0.83），P<0.01]。
坤泰与雌激素一样能有效改善绝经综合征症状，且不良反应发生率更低。
